Phase I CCR4 CAR T Cells gene therapy targeting CCR4 in T-cell lymphomas

This Phase I trial by the National Cancer Institute tests the safety of administering autologous T cells engineered with an anti-CCR4 CAR. Eligible adults have CCR4+ peripheral or cutaneous T-cell lymphomas that are refractory or relapsed. Participants undergo conditioning chemotherapy with cyclophosphamide and fludarabine before infusion, followed by imaging and laboratory assessments over a 15-year follow-up to evaluate this novel gene therapy approach.